Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
688 results
  • Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis. [Review]
    CNS Drugs 2019; 33(3):225-238Chen SY, Ravindran G, … Siskind D
  • CONCLUSIONS: Clozapine-induced sialorrhea is a potentially serious adverse event. Included studies in this meta-analysis were limited by poor study quality. Diphenhydramine, chlorpheniramine and benzamide derivatives appear to have the best supporting evidence and lowest reported adverse events. Caution should be exercised when using propantheline given its increased risk of constipation.
  • Drugs and Lactation Database (LactMed): Propantheline [BOOK]
    National Library of Medicine (US): Bethesda (MD)BOOK
  • No information is available on the use of propantheline during breastfeeding. Because propantheline is a quaternary ammonium compound, it is not likely to be absorbed and reach the bloodstream of the infant. Long-term use of propantheline might reduce milk production or milk letdown. During long-term use, observe for signs of decreased lactation (e.g., insatiety, poor weight gain).
  • Electrical stimulation with non-implanted electrodes for overactive bladder in adults. [Review]
    Cochrane Database Syst Rev 2016; 12:CD010098Stewart F, Gameiro LF, … Amaro JL
  • CONCLUSIONS: Electrical stimulation shows promise in treating OAB, compared to no active treatment, placebo/sham treatment, PFMT and drug treatment. It is possible that adding ES to other treatments such as PFMT may be beneficial. However, the low quality of the evidence base overall means that we cannot have full confidence in these conclusions until adequately powered trials have been carried out, measuring subjective outcomes and adverse effects.
  • An integrative review of standardized clinical evaluation tool utilization in anticholinergic drug trials for neurogenic lower urinary tract dysfunction. [Review]
    Spinal Cord 2016; 54(12):1114-1120Stothers L, Tsang B, … Macnab A
  • CONCLUSIONS: Integrative review of trials from 1946 to 2015 identified infrequent use of standardized clinical evaluation tools and reporting measures. Data from future trials evaluating therapies for neurogenic bladder would likely be more applicable to specific SCI patients if current standardized classification and descriptors now available were used consistently: for example, the ASIA scale, symptom scores validated in SCI, standardized urodynamic methodology, urinary diaries and urinary tract terminology. Studies recruiting SCI patients exclusively would also provide additional benefit.
New Search Next